Healthcare
Petros Pharmaceuticals, Inc.(PTPI)
Live Price
Offline$0.006
+0.00% today
1Y Change
-80.00%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -100.0%
- EPS Growth
- +304.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Petros Pharmaceuticals, Inc. (PTPI) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.01 and down 80.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +304.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +304.2%, free cash flow -180418.8% with operating margin 0.0% and ROIC 68.7%. Valuation is more restrained than many high-expectation growth names at P/E 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTPI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
P/E
Below sector median
0.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Nov 13, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +304.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 13, 2025 | โ | +0.0% | -17.6% | -23.5% |
2025 Aug 14, 2025 | โ | +0.0% | -9.7% | -9.7% |
2025 May 15, 2025 | โ | +0.0% | +13.3% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTPI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTPI Max Drawdown
-85.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTPI and SPY.
Company Overview
Petros Pharmaceuticals, Inc.
NASDAQ Capital Market
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
- Leadership
- Joshua N. Silverman
- IPO Date
- Dec 2, 2020
- Employees
- 18
- Street Address
- 1185 Avenue of the Americas
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 973-242-0005
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 0.0
- EV/EBITDA
- 1328.8
- Price/Sales
- โ
- Price/Book
- 0.0
Growth
- Revenue
- -100.0%
- EPS
- +304.2%
- Free Cash Flow
- -180418.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 266.8%
- ROIC
- 68.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.25
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.